CBUS
Cibus, Inc.
CBUS lost money over the past year, so it has no meaningful PE right now.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CBUS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
CBUS's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CBUS PE Valuation
CBUS has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CBUS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect CBUS's revenue to grow, with its earnings and profitability holding steady.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CBUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.30 | +$2.03 |
| Q2 2026 | -$1.45 | +$9.07 |
| Q1 2026 | -$1.77 | +$9.28 |
| Q4 2025 | -$2.78 | +$8.05 |
| Q3 2025 | -$3.33 | +$26.78 |
| Q2 2025 | -$10.52 | +$13.55 |
| Q1 2025 | -$11.05 | +$14.93 |
| Q4 2024 | -$10.83 | +$19.48 |
CBUS has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CBUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $800K | +30% |
| Q2 2026 | $994K | +6.5% |
| Q1 2026 | $1.7M | +63% |
| Q4 2025 | $1.1M | -13% |
| Q3 2025 | $615K | -63% |
| Q2 2025 | $933K | +11% |
| Q1 2025 | $1M | +90% |
| Q4 2024 | $1.2M | +9.9% |
CBUS's revenue is recovering but still below its 2020 peak: $800,000 last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1563% | +947 points |
| Q2 2026 | -1300% | +623 points |
| Q1 2026 | -721% | +3299 points |
| Q4 2025 | -2136% | -649 points |
| Q3 2025 | -2510% | +9514 points |
| Q2 2025 | -1923% | +640 points |
| Q1 2025 | -4020% | -635 points |
| Q4 2024 | -1487% | +22929 points |
CBUS's operating margin was −1563% last quarter, up 947 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CBUS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over CBUS on profitability, with a higher operating margin.
CBUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.3M | +$2.5M |
| Q2 2026 | -$9.4M | +$4.3M |
| Q1 2026 | -$11.6M | +$517K |
| Q4 2025 | -$13.5M | +$545K |
| Q3 2025 | -$11.8M | +$2M |
| Q2 2025 | -$13.7M | +$3.5M |
| Q1 2025 | -$12.1M | +$1.6M |
| Q4 2024 | -$14.1M | +$3.4M |
CBUS has burned cash in almost every quarter: −$44M over the past year, against −$52M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CBUS on cash generation, producing positive trailing cash flow while its opponent burns cash.
CBUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +137K shares |
| 1 year | +45% | +24M shares |
| 3 years | +7682% | +75.9M shares |
| 5 years | +10253% | +76.2M shares |
| Available history | +11620% | +76.2M shares |
CBUS has 77M diluted shares, up 45% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CBUS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CBUS Net Leverage
CBUS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CBUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 4.7 | Oversold |
CBUS's weekly RSI is 38 (neutral) and its Stochastic is 5 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CBUS PE vs Healthcare Sector
CBUS has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CBUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.38 | 21% below |
| 20 week MA | $1.58 | 31% below |
| 50 week MA | $1.77 | 38% below |
| 100 week MA | $1.82 | 40% below |
| 200 week MA | $8.07 | 86% below |
CBUS is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CBUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $320.5 | $215.5 | -33% |
| 2021 | $215.5 | $111.5 | -48% |
| 2022 | $111.5 | $6.60 | -94% |
| 2023 | $6.60 | $19.6 | +198% |
| 2024 | $19.6 | $2.36 | -88% |
| 2025 | $2.36 | $1.70 | -28% |
| 2026 YTD | $1.70 | $1.09 | -36% |
CBUS has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.